Apellis Pharmaceuticals, Inc. APLS NASDAQ

Apellis Pharmaceuticals, Inc. (APLS) generated $45.33M in operating cash flow for fiscal year 2025. After capital expenditures of $313K, free cash flow was $45.01M.

Free cash flow margin was 4.5% of revenue. Cash conversion ratio was 2.02x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (65/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (30/100) — Cash conversion ratio was 2.02x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 48/100 with 1/7 criteria passed.